|
|
|
|
|
My Recent Searches
|
|
|
|
|
|
|
|
$0.00 0.00 (0.00%) as of 4:30 Tue 11/30
|
|
Download |
|
|
|
|
Exchange: |
N/A |
Security
Type: |
N/A |
Shares
Out: |
107,850,000 |
Market
Cap: |
N/A |
Last
Volume: |
0 |
Avg
Vol: |
0 |
52
Week Range: |
$ - $ |
|
Level
I Sector: |
N/A |
Level
II Sector: |
N/A |
Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
Insider 3 Months : - |
Insider 6 Months : - |
Insider 3/6 Months : - |
|
Guru Rank Number : - |
Guru Rank Value : - |
Guru Occurances : - |
|
|
|
|
|
|
|
Company Profile Vaxcyte is a clinical-stage vaccine company. Co. is developing conjugate and protein vaccines to treat bacterial infectious diseases. Co.'s primary vaccine candidate, VAX-24, is a 24-valent investigational pneumococcal conjugate vaccine (PCV) for the treatment of invasive pneumococcal disease and pneumonia. Co.'s second PCV candidate, VAX-XP, is designed to expand the breadth of coverage to greater than 30 strains without compromising immunogenicity due to carrier suppression. In addition, Co.'s pipeline includes VAX-A1, a conjugate vaccine candidate designed to treat Group A Strep and VAX-PG, a protein vaccine candidate targeting the keystone pathogen responsible for periodontitis.
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
3m +/-:
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
Actions:
|
|
|
B |
Buy |
S |
Sell |
OE |
Option
Exercised |
A |
Acquired |
D |
Disposed |
AB |
Automatic
Buy |
AS |
Automatic
Sell |
IO |
Initial
Ownership |
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
|
|
Summary (Direct Transactions Only) |
3 Months |
6 Months |
12 Months |
24 Months |
Total Shares Bought |
0 |
0 |
0 |
0 |
Total Buy Value |
$0 |
$0 |
$0 |
$0 |
Total People Bought |
0 |
0 |
0 |
0 |
Total Buy Transactions |
0 |
0 |
0 |
0 |
Total Shares Sold |
124,527 |
289,711 |
366,947 |
559,547 |
Total Sell Value |
$8,826,266 |
$19,152,247 |
$23,008,468 |
$28,095,276 |
Total People Sold |
5 |
6 |
6 |
8 |
Total Sell Transactions |
16 |
36 |
45 |
80 |
End Date |
2024-02-22 |
2023-11-21 |
2023-05-23 |
2022-05-23 |
|
Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
Hopfner Robert Lorne |
Director |
|
2021-01-25 |
4 |
AS |
$25.61 |
$902,745 |
I/I |
(34,972) |
1,823,400 |
|
- |
|
Hopfner Robert Lorne |
Director |
|
2021-01-22 |
4 |
AS |
$25.16 |
$286,396 |
I/I |
(11,383) |
1,858,372 |
|
- |
|
Hopfner Robert Lorne |
Director |
|
2021-01-21 |
4 |
AS |
$25.11 |
$2,511 |
I/I |
(100) |
1,869,755 |
|
- |
|
Hopfner Robert Lorne |
Director |
|
2021-01-20 |
4 |
AS |
$25.35 |
$482,816 |
I/I |
(19,046) |
1,869,855 |
|
- |
|
Wassil Jim |
Chief Operating Officer |
|
2021-01-20 |
4 |
AS |
$25.50 |
$76,500 |
D/D |
(3,000) |
16,381 |
|
- |
|
Wassil Jim |
Chief Operating Officer |
|
2021-01-20 |
4 |
OE |
$2.42 |
$7,260 |
D/D |
3,000 |
19,381 |
|
- |
|
Pickering Grant |
President & CEO |
|
2021-01-19 |
4 |
AS |
$25.01 |
$376,498 |
D/D |
(15,000) |
578,691 |
|
- |
|
Pickering Grant |
President & CEO |
|
2021-01-19 |
4 |
OE |
$1.79 |
$26,850 |
D/D |
15,000 |
593,691 |
|
- |
|
Hopfner Robert Lorne |
Director |
|
2021-01-19 |
4 |
AS |
$25.55 |
$1,268,634 |
I/I |
(49,516) |
1,888,901 |
|
- |
|
Mitchell Jane Wright |
General Counsel |
|
2021-01-15 |
4 |
AS |
$26.00 |
$65,000 |
D/D |
(2,500) |
1,562 |
|
- |
|
Mitchell Jane Wright |
General Counsel |
|
2021-01-15 |
4 |
OE |
$2.03 |
$5,075 |
D/D |
2,500 |
4,062 |
|
- |
|
Hopfner Robert Lorne |
Director |
|
2021-01-15 |
4 |
AS |
$25.74 |
$687,846 |
I/I |
(26,677) |
1,938,417 |
|
- |
|
Hopfner Robert Lorne |
Director |
|
2021-01-14 |
4 |
AS |
$25.88 |
$386,078 |
I/I |
(14,918) |
1,965,094 |
|
- |
|
Hopfner Robert Lorne |
Director |
|
2021-01-13 |
4 |
AS |
$25.90 |
$755,313 |
I/I |
(29,110) |
1,980,012 |
|
- |
|
Hopfner Robert Lorne |
Director |
|
2021-01-12 |
4 |
AS |
$26.35 |
$489,871 |
I/I |
(18,567) |
2,009,122 |
|
- |
|
Hopfner Robert Lorne |
Director |
|
2021-01-11 |
4 |
AS |
$25.42 |
$1,313,764 |
I/I |
(49,666) |
2,027,689 |
|
- |
|
Sauer Paul |
SVP Process Dev, Manufacturing |
|
2021-01-11 |
4 |
AS |
$25.38 |
$65,527 |
D/D |
(2,500) |
77,899 |
|
- |
|
Sauer Paul |
SVP Process Dev, Manufacturing |
|
2021-01-11 |
4 |
OE |
$1.79 |
$4,475 |
D/D |
2,500 |
80,399 |
|
- |
|
Hopfner Robert Lorne |
Director |
|
2021-01-08 |
4 |
AS |
$26.43 |
$1,079,549 |
I/I |
(40,612) |
2,077,355 |
|
- |
|
Hopfner Robert Lorne |
Director |
|
2021-01-07 |
4 |
AS |
$27.75 |
$1,344,887 |
I/I |
(47,580) |
2,117,967 |
|
- |
|
Hopfner Robert Lorne |
Director |
|
2021-01-06 |
4 |
AS |
$29.24 |
$1,695,841 |
I/I |
(57,420) |
2,165,547 |
|
- |
|
Fairman Jeff |
VP, Research |
|
2020-12-29 |
4 |
OE |
$1.79 |
$1,325 |
D/D |
740 |
1,408 |
|
- |
|
Pickering Grant |
President & CEO |
|
2020-12-28 |
4 |
OE |
$1.79 |
$9,845 |
D/D |
5,500 |
578,691 |
|
- |
|
Pickering Grant |
President & CEO |
|
2020-12-21 |
4 |
AS |
$28.42 |
$433,141 |
D/D |
(15,000) |
573,191 |
|
- |
|
Pickering Grant |
President & CEO |
|
2020-12-21 |
4 |
OE |
$1.79 |
$26,850 |
D/D |
15,000 |
588,191 |
|
- |
|
349 Records found
|
|
Page 13 of 14 |
|
|
|
Transaction Code Key: |
Ownership Code Key |
|
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
|
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Acquired |
|
IO |
- Initital Ownership |
D |
- Disposed |
|
|
|
|
|
|